India's ambition to raise research and development spending toward 3% of GDP is entering a more practical phase, with the Anusandhan National Research Foundation signalling that the country must build a financing architecture capable of sustaining long-horizon innovation. Speaking on the challenge of scaling India's research multiplier, ANRF chief executive Shivkumar Kalyanaraman framed the issue not as a shortage of ideas, but as a shortage of capital structures that can absorb scientific risk and support translation from lab to market.
Kalyanaraman's central argument is that India cannot rely on conventional venture timelines or purely public funding if it wants to move from incremental progress to a deeper research economy. His formulation of a "patient-capital architecture" reflects a broader policy shift: research must be treated as an asset class with long gestation periods, where returns may emerge through licensing, platform creation, manufacturing spillovers and strategic national capability rather than immediate revenue.
Patient Capital Model
The ANRF framework is designed to bridge a familiar gap in India's innovation system. The country has produced strong startup activity in software, fintech and consumer technology, but it has historically struggled to convert scientific research into durable deep-tech enterprises at scale. Kalyanaraman's approach seeks to address that bottleneck by combining private investment with public mission funding and open intellectual property licensing, creating a structure in which early-stage research can be de-risked before commercial investors step in.
That matters because India's research intensity remains well below the level of advanced innovation economies. Moving toward 3% of GDP will require not only larger budgets, but also better coordination between universities, laboratories, startups, industry and government programmes. The ANRF's role is increasingly being seen as catalytic: to shape incentives, reduce fragmentation and ensure that public money helps crowd in private capital rather than substitute for it.
The emphasis on open IP licensing is especially significant. In India, one of the persistent weaknesses in the innovation chain has been the slow transfer of publicly funded research into usable products. By encouraging licensing models that are open, structured and scalable, the ANRF hopes to lower transaction costs for startups and industry partners while preserving the public value of foundational research. In effect, the aim is to make knowledge more mobile.
Mission-Led Innovation
Kalyanaraman's remarks also point to a more mission-oriented model of innovation policy. National mission programmes, if properly designed, can create demand certainty for technologies that would otherwise struggle to find early customers. That is particularly relevant in sectors such as clean energy, advanced materials, biotech, semiconductors and strategic manufacturing, where the market often needs a public-sector anchor before private capital is willing to commit at scale.
For startups and venture investors, the implication is clear: India's next wave of high-value companies may depend less on rapid consumer adoption and more on patient participation in nationally important technology programmes. This could widen the opportunity set for deep-tech founders, but it also raises the bar for execution. Research commercialisation requires stronger university-industry ties, more experienced technology transfer mechanisms and a willingness among investors to tolerate longer timelines.
The policy challenge is not merely to spend more, but to spend in ways that multiply. A research multiplier rises when one rupee of public funding attracts additional private investment, generates intellectual property, supports skilled jobs and produces downstream industrial capability. That is the logic behind the ANRF's architecture: public capital should unlock ecosystems, not just projects.
India's Innovation Test
The timing of this push is notable. India's startup ecosystem has matured, but funding conditions for capital-intensive innovation remain selective, especially in a global environment where investors are more cautious about long-duration bets. By advocating patient capital, the ANRF is effectively arguing that India's innovation policy must be insulated from short-term market cycles if it is to build sovereign capability in science and technology.
The broader economic case is substantial. If India can improve the conversion rate from research to commercial application, it could strengthen productivity, reduce import dependence in strategic sectors and create new export categories. But the transition will require discipline: transparent governance, measurable milestones and a clear division of responsibilities between state institutions, private investors and research performers.
Kalyanaraman's message is ultimately one of urgency. India does not need to wait generations to build a stronger research economy, he suggested, and it should not accept a 75-year timeline for outcomes that can be accelerated through better capital design. The question now is whether the country's policy apparatus, investors and institutions can align around that premise quickly enough to turn ambition into scale.